Peer-reviewed veterinary case report
Radiation therapy outcomes for advanced anal sac cancer in 77 dogs
By McQuown, B et al.·Published in Veterinary and comparative oncology·2017·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of advanced canine anal sac adenocarcinoma with hypofractionated radiation therapy: 77 cases (1999-2013).
- Species:
- dog
Plain-English summary
A group of 77 dogs with advanced anal sac adenocarcinoma (a type of cancer near the anus) received hypofractionated radiation therapy to see if it could help. About 38% of the dogs showed some improvement, and 63% had a reduction or complete resolution of symptoms related to the tumor. For those with high calcium levels due to the cancer, 31% improved with radiation alone, and an additional 46% improved when radiation was combined with other medications. Most dogs tolerated the treatment well, and the average survival time after starting therapy was about 11 months.
People also search for: dog anal sac cancer treatment · radiation therapy for dog cancer · advanced anal sac adenocarcinoma in dogs
Abstract
Currently no standard of care exists for advanced, inoperable or metastatic anal sac adenocarcinoma (ASAC). The objective of this retrospective study was to assess the role of hypofractionated radiation therapy (RT) in 77 dogs with measurable ASAC. A total of 38% of dogs experienced a partial response to RT. For dogs presenting with clinical signs related to the tumour, improvement or resolution of signs was noted in 63%. For dogs presenting with hypercalcemia of malignancy, resolution was noted in 31% with RT alone and an additional 46% with radiation, prednisone, and/or bisphosphonates. Median overall survival was 329 days (range: 252-448 days). Median progression free survival was 289 days (range: 224-469). There was no difference in survival based on radiation protocol, use of chemotherapy, previous surgery or advanced stage. Radiation toxicities were mild and infrequent. Hypofractionated RT is well tolerated and is applicable in the treatment of advanced primary, locoregional or metastatic ASAC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26991552/